Dr. Kemeny on Liver-Directed Therapy for Metastatic CRC

Nancy E. Kemeny, MD
Published: Wednesday, Dec 13, 2017



Nancy E. Kemeny, MD, a medical oncologist at Memorial Sloan Kettering Cancer Institute, discusses liver-directed therapies for patients with metastatic colorectal cancer (CRC).

Although there are new drugs for the treatment of CRC, there are still many patients who die from metastatic disease, explains Kemeny. According to Kemeny, 70% of patients with metastatic disease will have liver metastases.

It is important to direct chemotherapy into the liver to help those patients, says Kemeny. Giving drugs straight to the liver either in first-line or beyond could achieve better results.
 


Nancy E. Kemeny, MD, a medical oncologist at Memorial Sloan Kettering Cancer Institute, discusses liver-directed therapies for patients with metastatic colorectal cancer (CRC).

Although there are new drugs for the treatment of CRC, there are still many patients who die from metastatic disease, explains Kemeny. According to Kemeny, 70% of patients with metastatic disease will have liver metastases.

It is important to direct chemotherapy into the liver to help those patients, says Kemeny. Giving drugs straight to the liver either in first-line or beyond could achieve better results.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x